Biotechnology
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or 'ANVISA') has approved Illuccix® (kit fo...
2025-03-18 06:52
2635
Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia
SHANGHAI, March 17, 2025 /PRNewswire/ -- Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) for RN0361-an APOC3 targeted siRNA (small interfering RNA) therapeutic for se...
2025-03-17 19:00
3853
AIM Vaccine reported a significant reduction in losses for 2024, with several major products set to launch that are expected to drive substantial revenue growth
HONG KONG, March 17, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onMarch 17, 2025, the company's performance in 2024 showed a significant reduction in losses. Preliminary assessments indicate that the company's revenue is expecte...
2025-03-17 14:30
3249
HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease
* Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED). * Batoclimab, subcutaneous formulation, offers the potential for at-home administration, improving patient convenience and accessibility. * Phase 3 study to confirm the potential...
2025-03-17 07:59
2302
Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025
Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targetingHuntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO International Congress inPrague, Czech Republic. BOSTON, March 15, 2025 /PRNewswire/ -- Skyhawk Therapeut...
2025-03-15 18:07
3243
Telix Adds Lead-212 Isotope Production Capability
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed...
2025-03-13 06:48
3545
Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership
CASTRES, France, CAMBRIDGE, Massachusetts and BASEL, Switzerland, March 12, 2025 /PRNewswire/ -- Pierre Fabre Laboratories and RedRidge Bio ("RedRidge") today announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against ...
2025-03-12 17:00
2127
SPRIM Global Investments and OneIM Announce $300mn Joint Venture to Accelerate Clinical Trial Financing
SINGAPORE and NEW YORK, March 10, 2025 /PRNewswire/ -- SPRIM Global Investments ("SGI"), a global investment firm specializing in clinical-stage life sciences and pharma services based inSingapore, and One Investment Management ("OneIM"), a global alternative investment management firm, today ann...
2025-03-10 20:19
2444
Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) was approved ...
2025-03-10 19:22
1895
Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine
* The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoantigen prediction algorithm and clinically validated mRNA platform progress into human trials. * In preclinical studies, EVM16 demonstrated...
2025-03-06 16:30
2223
Newly-formed Archerfish Precision Diagnostics Pte Ltd: Ushers a New Era in Advanced Diagnostics
SINGAPORE, March 6, 2025 /PRNewswire/ -- In a significant development for the clinical diagnostics landscape inSingapore, Angsana Molecular & Diagnostics Laboratory (Angsana) and Pathnova Laboratories (Pathnova) have announced their merger to formArcherfish Precision Diagnostics Private Limited (...
2025-03-06 11:52
2061
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy, announced today optimistic results from its ongoing clinical trial evaluating LAM561 for the treatment of newly diagnosed glioblastoma ...
2025-03-05 22:45
1900
Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director
ROCKVILLE, Md., March 5, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend)
2025-03-05 22:33
2431
Prenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance
Revenue grew 93.5% to $10.5 million in the fourth quarter and 40.9% year-over-year to$30.6 million in 2024 Cash and short-term assets of $84.8 million as of December 31, 2024 Provides first quarter and full year 2025 guidance Projects full year 2025 revenue of $73 million to $85 million, driven ...
2025-03-05 21:32
4038
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO® has been approved for multiple ind...
2025-03-05 13:00
2335
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
* Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience * Financing led by Frazier Life Sciences with significant participation from Jeito Capital alongside o...
2025-03-03 22:00
2666
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
* First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model * Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VA...
2025-03-03 21:00
1578
Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2025-03-03 08:00
4223
A*STAR And MojiaBio To Develop Next-gen Sustainable Biomanufacturing Platform In Singapore
SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- This initiative aims to produce
eco-friendly bio-based molecules from low-cost, eco-friendly sources. Key
benefits include:
2025-02-28 18:00
2549
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
SHANGHAI, Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor...
2025-02-28 14:28
4185
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
